Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 1 The heterogenous landscape of triple-negative breast cancer

Advertisements

Reproduced with permission from Cronin M et al

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 3 Intracranial targeting of high-grade gliomas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 1 The multidomain structure of c-MET and its ligand, HGF

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 HGF/c-MET signalling pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 The biological effects of charged particles

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 A schematic representation of the role

chemotherapy for patients with MC versus those with AC

to the liver and promote patient-derived xenograft tumour growth

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 2 The patterns of epithelial-to-mesenchymal

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Intravenous delivery of reovirus to primary and secondary brain tumors

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Volume 77, Issue 9, Pages (May 2010)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Immunohistochemical staining of primary and metastatic prostatic carcinomas with anticyclin D1 and anti-Ki67 monoclonal antibodies. Immunohistochemical.

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.40 Figure 4 Stratification biomarkers to identify MET-dependent colorectal cancers (CRCs) Figure 4 | Stratification biomarkers to identify MET-dependent colorectal cancers (CRCs). a | MET to chromosome 7 double-silver in situ hybridization (DISH) in CRC primary formalin-fixed paraffin-embedded tissue. b | MET RNA in situ hybridization in liver metastases from a patient with CRC. c–e | Representative images of c-MET immunohistochemical staining using the CONFIRM SP44 anti-MET rabbit monoclonal antibody in core biopsy samples of CRC liver metastasis showing heterogeneous immunoreactivity (defined as samples with specific regions with a c-MET stratification score of 1+ and others with a score of 3+) for c-MET. Bradley, C. A. et al. (2017) Targeting c‑MET in gastrointestinal tumours: rationale, opportunities and challenges Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.40